Department of Nephrology, Second Affiliated Hospital, Shantou University Medical College, Shantou, China.
Front Endocrinol (Lausanne). 2022 Jul 28;13:962635. doi: 10.3389/fendo.2022.962635. eCollection 2022.
Diabetic kidney disease (DKD) is one of complications of diabetes mellitus with severe microvascular lesion and the most common cause of end-stage chronic kidney disease (ESRD). Controlling serum glucose remains the primary approach to preventing and slowing the progression of DKD. Despite considerable efforts to control diabetes, people with diabetes develop not only DKD but also ESRD. The pathogenesis of DKD is very complex, and current studies indicate that mesenchymal stromal cells (MSCs) regulate complex disease processes by promoting pro-regenerative mechanisms and inhibiting multiple pathogenic pathways. Extracellular vesicles (EVs) are products of MSCs. Current data indicate that MSC-EVs-based interventions not only protect renal cells, including renal tubular epithelial cells, podocytes and mesangial cells, but also improve renal function and reduce damage in diabetic animals. As an increasing number of clinical studies have confirmed, MSC-EVs may be an effective way to treat DKD. This review explores the potential efficacy and signaling pathways of MSC-EVs in the treatment of DKD.
糖尿病肾病(DKD)是糖尿病严重微血管病变的并发症之一,也是终末期慢性肾脏病(ESRD)的最常见病因。控制血清葡萄糖仍然是预防和减缓 DKD 进展的主要方法。尽管人们为控制糖尿病付出了巨大努力,但糖尿病患者不仅会发生 DKD,还会发生 ESRD。DKD 的发病机制非常复杂,目前的研究表明,间充质基质细胞(MSCs)通过促进促再生机制和抑制多种致病途径来调节复杂的疾病过程。细胞外囊泡(EVs)是 MSC 的产物。目前的数据表明,基于 MSC-EVs 的干预不仅可以保护包括肾小管上皮细胞、足细胞和系膜细胞在内的肾细胞,还可以改善糖尿病动物的肾功能并减少损伤。随着越来越多的临床研究证实,MSC-EVs 可能是治疗 DKD 的有效方法。本综述探讨了 MSC-EVs 在治疗 DKD 中的潜在疗效和信号通路。